Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GCC Agonist Signal in the Small Intestine

Major Program

Cancer Prevention Clinical Trials Network

Research Group

Gastrointestinal and Other Cancers

Status

Active, not recruiting

NCT ID

NCT05107219

This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.

Intervention

Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide

Condition

Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm

Investigators

David S Weinberg, David S. Weinberg

CT Research Area

Prevention

See list of participating sites